BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28609484)

  • 1. The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
    Bjersand K; Seidal T; Sundström-Poromaa I; Åkerud H; Skirnisdottir I
    PLoS One; 2017; 12(6):e0179363. PubMed ID: 28609484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
    Skirnisdottir I; Seidal T
    Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
    Skírnisdóttir I; Seidal T
    Oncol Rep; 2012 Mar; 27(3):741-7. PubMed ID: 22159712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II.
    Skirnisdottir I; Seidal T; Åkerud H
    Int J Oncol; 2016 Mar; 48(3):998-1006. PubMed ID: 26783205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir IA; Sorbe B; Lindborg K; Seidal T
    Int J Gynecol Cancer; 2011 Feb; 21(2):236-44. PubMed ID: 21270607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer.
    Shen W; Li HL; Liu L; Cheng JX
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2596-2603. PubMed ID: 28678326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
    Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
    Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma.
    Skirnisdottir I; Seidal T; Åkerud H
    Int J Gynecol Cancer; 2015 Sep; 25(7):1239-47. PubMed ID: 26035126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma.
    Liu Y; Yang L; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Sci Rep; 2015 Nov; 5():16954. PubMed ID: 26599282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
    Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
    Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer.
    Wang M; He Y; Shi L; Shi C
    Eur J Gynaecol Oncol; 2011; 32(2):171-7. PubMed ID: 21614907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages I-II.
    Skirnisdottir I; Åkerud H; Seidal T
    Int J Oncol; 2018 Oct; 53(4):1633-1642. PubMed ID: 30066848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Napsin A as a marker of clear cell ovarian carcinoma.
    Skirnisdottir I; Bjersand K; Akerud H; Seidal T
    BMC Cancer; 2013 Nov; 13():524. PubMed ID: 24191930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.